Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants

Overview of attention for article published in JAMA: Journal of the American Medical Association, October 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 3 news outlets
blogs: 3 blogs
twitter: 43 X users

facebook: 2 Facebook pages
guideline: 1 clinical guideline source
bluesky: 10 Bluesky users

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 14 Bluesky posts from 10 Bluesky users, with an upper bound of 26,932 followers.

Intratracheal steroids added to surfactant therapy do not reduce the risk of lung disease or death in extremely preterm infants, according to results from a large multicenter clinical trial. doi.org/hbbp66

RP @medicine.stitches.today: Budesonide Plus Surfactant Fails to Reduce BPD or Death in Extremely Preterm Infants, Raises Hyperglycemia Risk by Ambalavanan N, Carlo WA (...) Walsh MC et 35 al. in JAMA #MedSky 👉 get more here 📖 read the article: https…

Budesonide Plus Surfactant Fails to Reduce BPD or Death in Extremely Preterm Infants, Raises Hyperglycemia Risk by Ambalavanan N, Carlo WA (...) Walsh MC et 35 al. in JAMA #MedSky 👉 get more here 📖 read the article: https://jamanetwork.com/journals/j…

RP @jama.com: In extremely preterm infants, intratracheal budesonide mixed with surfactant did not reduce bronchopulmonary dysplasia or death by 36 weeks' postmenstrual age. ja.ma/4hIhT2P

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 10 additional Bluesky posts.